Targeting Pancreatic Cancer with Novel Nicolaioidesin C Derivatives: Molecular Mechanism, <i>In Vitro</i>, and <i>In Vivo</i> Evaluations-Reference-Cited by-同舟云学术

Targeting Pancreatic Cancer with Novel Nicolaioidesin C Derivatives: Molecular Mechanism, In Vitro, and In Vivo Evaluations

Published:2024-08-06 Issue:16 Volume:67 Page:14313-14328
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Yamazaki Takeyoshi¹²,Phan Nguyen Duy¹²,Maneenet Juthamart¹,Yamagishi Mitsuki³,Nishikawa Yuya⁴,Okada Takuya⁴⁵^ORCID,Okumura Tomoyuki²,Toyooka Naoki⁴⁵^ORCID,Fujii Tsutomu²^ORCID,Awale Suresh¹^ORCID

Affiliation:

1. Natural Drug Discovery Laboratory, Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan

2. Department of Surgery and Science, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama 930-0194, Japan

3. Graduate School of Pharma-Medical Sciences, University of Toyama, Toyama 930-8555, Japan

4. Faculty of Engineering, University of Toyama, Toyama 930-8555, Japan

5. Graduate School of Science and Engineering, University of Toyama, Toyama, 930-8555, Japan

Funder

Japan Society for the Promotion of Science

University of Toyama

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.4c01141

Reference33 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Remnant Pancreatic Cancer After Surgical Resection for Pancreatic Cancer

3. Early detection of pancreatic cancer

4. Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review

5. Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach